Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA files NDI for Lipowheat oil

This article was originally published in The Tan Sheet

Executive Summary

FDA accepts without objection a new dietary ingredient application for Lipowheat oil - giving the developer Hitex tacit approval to market the "all natural vegetable extract" in the U.S., according to an April 4 release. The ingredient is "the only source of natural ceramide on the market with an NDI on file," according to P.L. Thomas, the North American distributor for the ingredient. Ceramides, along with cholesterol and free fatty acids, are the lipids that help bind together the cells of the skin's stratum corneum and play an important role in skin hydration, the company explains. Thomas - and formulators that use the ingredient - claim Lipowheat oil "restores the skin barrier function, ensuring a healthy hydration mechanism." The ingredient can be used in skin-hydrating supplements or drinks supported by clinical trials
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS103989

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel